Showing 1481-1490 of 2656 results for "".
- Moderna’s Variant-Specific COVID-19 Vaccine Candidate Ready for Clinical Testinghttps://modernod.com/news/modernas-variant-specific-covid-19-vaccine-candidate-ready-for-clinical-testing/2478914/Moderna said that it has manufactured the initial batch of an updated version of its COVID-19 vaccine designed to better protect against the B.1.351 variant of SARS-CoV-2 first identified in South Africa. The company indicated late last month that it would be working on the variant-specific boost
- New World Medical’s Next-Generation KDB GLIDE Now Commercially Availablehttps://modernod.com/news/new-world-medicals-next-generation-kdb-glide-now-commercially-available/2478880/New World Medical announced the launch of the KDB GLIDE device for advanced excisional goniotomy treatment of glaucoma. The KDB GLIDE, which was registered with the FDA in October 2020, is now commercially available to ophthalmic surgeons across the US looking for refined, precise performance dur
- FDA Clears Lilly’s COVID-19 Antibody Duo Bamlanivimab, Etesevimab for Emergency Usehttps://modernod.com/news/fda-clears-lillys-covid-19-antibody-duo-bamlanivimab-etesevimab-for-emergency-use/2478854/Eli Lilly said Tuesday that it received FDA emergency-use authorization (EUA) for a neutralizing antibody cocktail combining bamlanivimab with etesevimab to treat mild-to-moderate COVID-19 in patients 12 and older who are at high risk for progressing to severe disease and/or hospitalization. Acco
- Novavax’s COVID-19 Vaccine Over 89% Effective in UK trial, Less So in South Africa Studyhttps://modernod.com/news/novavaxs-covid-19-vaccine-over-89-effective-in-uk-trial-less-so-in-south-africa-study/2478809/Novavax shares gained as much as 26% on Thursday after the company said its protein-based COVID-19 vaccine candidate NVX-CoV2373 met the primary endpoint of a phase 3 trial in the UK, demonstrating an efficacy rate of over 89%, with high protection also seen against the fast-spreading UK variant.
- Regeneron’s Antibody Cocktail Shows Promise as ‘Passive Vaccine’ Against COVID-19https://modernod.com/news/regenerons-antibody-cocktail-shows-promise-as-passive-vaccine-against-covid-19/2478804/Regeneron Pharmaceuticals reported initial results from a phase 3 study showing that, compared to placebo, its antibody cocktail REGEN-COV (casirivimab/imdevimab) reduced overall COVID-19 infections seen within the first week among people at high risk of contracting SARS-CoV-2, with 100% pr
- Genentech’s Faricimab Meets Primary Endpoint in Two Global Phase 3 Studies in Wet AMDhttps://modernod.com/news/genentechs-faricimab-meets-primary-endpoint-in-two-global-phase-3-studies-in-wet-amd/2478792/Genentech announced positive topline results from two identically designed global phase 3 studies, TENAYA and LUCERNE, evaluating its investigational bispecific antibody, faricimab, in people living with wet age-related macular degeneration (AMD). Both studies met their primary endpoint and showe
- Lilly’s Bamlanivimab Cuts Risk of COVID-19 By Up to 80% at Nursing Homeshttps://modernod.com/news/lillys-bamlanivimab-cuts-risk-of-covid-19-by-up-to-80-at-nursing-homes/2478788/Eli Lilly announced Thursday that in a phase 3 study, bamlanivimab was shown to significantly reduce the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities. The findings from the BLAZE-2 COVID-19 prevention trial suggest the risk was decreased by up to
- New Data Back Ability of Pfizer, BioNTech’s COVID-19 Vaccine to Foil UK Strainhttps://modernod.com/news/new-data-back-ability-of-pfizer-biontechs-covid-19-vaccine-to-foil-uk-strain/2478782/Pfizer and BioNTech on Wednesday reported results from another in-vitro study indicating that their COVID-19 vaccine BNT162b2 is likely capable of neutralizing the rapidly spreading UK strain of SARS-CoV-2, also known as B.1.1.7. The findings, which were published on the preprint server bioRxiv,
- CorNeat Vision’s First Patient Regains Sight Following Artificial Cornea Implantation at Rabin Medical Centerhttps://modernod.com/news/corneat-visions-first-patient-regains-sight-following-artificial-cornea-implantation-at-rabin-medical-center/2478741/The CorNeat KPro, an artificial cornea that integrates with the eye wall with no reliance on donor tissue, was successfully implanted in a human. The surgery was performed on a bilaterally blind, 78-year-old male at Rabin Medical Center, Israel, by Professor
- No Red Flags in FDA Review of Pfizer, BioNTech’s COVID-19 Vaccine Candidatehttps://modernod.com/news/no-red-flags-in-fda-review-of-pfizer-biontechs-covid-19-vaccine-candidate/2478641/In briefing documents released Tuesday ahead of an FDA advisory committee meeting on December 10, agency staff said that efficacy data submitted by Pfizer and BioNTech in support of BNT162b2 are “consistent” with recommendations previously detailed in guidance on the emergency-use aut